Eyepoint Pharmaceuticals’ (EYPT) “Buy” Rating Reiterated at Chardan Capital

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a research report issued on Friday,Benzinga reports. They currently have a $65.00 target price on the stock. Chardan Capital’s price target points to a potential upside of 406.63% from the stock’s previous close.

EYPT has been the subject of several other research reports. Guggenheim reaffirmed a “buy” rating and set a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. Cantor Fitzgerald lifted their price objective on shares of Eyepoint Pharmaceuticals from $47.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday. Royal Bank Of Canada dropped their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, HC Wainwright reduced their price target on shares of Eyepoint Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.38.

Eyepoint Pharmaceuticals Stock Performance

NASDAQ:EYPT opened at $12.83 on Friday. Eyepoint Pharmaceuticals has a fifty-two week low of $9.65 and a fifty-two week high of $19.11. The company has a 50 day simple moving average of $13.10 and a two-hundred day simple moving average of $13.78. The company has a market capitalization of $1.08 billion, a PE ratio of -3.43 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.13). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 124.86%. The firm had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. Research analysts predict that Eyepoint Pharmaceuticals will post -3.3 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. KBC Group NV bought a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after acquiring an additional 1,358 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after acquiring an additional 794 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Eyepoint Pharmaceuticals during the third quarter valued at approximately $76,000. Finally, Persistent Asset Partners Ltd bought a new stake in Eyepoint Pharmaceuticals during the fourth quarter worth $98,000. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.